Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 inhibitors and thermal ablation in advanced HCC
NCT03939975Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, nivolumab, toripalimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03939975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939975.